| Efficacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells W Onstenk, AM Sieuwerts, J Kraan, M Van, AJM Nieuweboer, ... European urology 68 (6), 939-945, 2015 | 245 | 2015 |
| Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting DJE Peeters, B De Laere, GG Van den Eynden, SJ Van Laere, F Rothé, ... British journal of cancer 108 (6), 1358-1367, 2013 | 178 | 2013 |
| Comprehensive profiling of the androgen receptor in liquid biopsies from castration-resistant prostate cancer reveals novel intra-AR structural variation and splice variant … B De Laere, PJ van Dam, T Whitington, M Mayrhofer, EH Diaz, ... European urology 72 (2), 192-200, 2017 | 120 | 2017 |
| TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate CancerComprehensive AR and TP53 … B De Laere, S Oeyen, M Mayrhofer, T Whitington, PJ van Dam, ... Clinical cancer research 25 (6), 1766-1773, 2019 | 115 | 2019 |
| Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis M Mayrhofer, B De Laere, T Whitington, P Van Oyen, C Ghysel, J Ampe, ... Genome medicine 10 (1), 1-13, 2018 | 104 | 2018 |
| Differential impact of RB status on E2F1 reprogramming in human cancer C McNair, K Xu, AC Mandigo, M Benelli, B Leiby, D Rodrigues, J Lindberg, ... The Journal of clinical investigation 128 (1), 341-358, 2018 | 85 | 2018 |
| Evaluation and consequences of heterogeneity in the circulating tumor cell compartment A Brouwer, B De Laere, D Peeters, M Peeters, R Salgado, L Dirix, ... Oncotarget 7 (30), 48625, 2016 | 60 | 2016 |
| Consensus statement on circulating biomarkers for advanced prostate cancer. S Sumanasuriya, AG Omlin, AJ Armstrong, G Attard, KN Chi, CL Bevan, ... Journal of Clinical Oncology 36 (6_suppl), 299-299, 2018 | 32 | 2018 |
| Circulating tumor cells and survival in abiraterone‐and enzalutamide‐treated patients with castration‐resistant prostate cancer B De Laere, S Oeyen, P Van Oyen, C Ghysel, J Ampe, P Ost, W Demey, ... The Prostate 78 (6), 435-445, 2018 | 24 | 2018 |
| AR splice variants in circulating tumor cells of patients with castration‐resistant prostate cancer: relation with outcome to cabazitaxel AM Sieuwerts, W Onstenk, J Kraan, CM Beaufort, M Van, B De Laere, ... Molecular Oncology 13 (8), 1795-1807, 2019 | 19 | 2019 |
| The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer A Crippa, B De Laere, A Discacciati, B Larsson, JT Connor, EE Gabriel, ... Trials 21 (1), 1-10, 2020 | 18 | 2020 |
| An in-depth evaluation of the validity and logistics surrounding the testing of AR-V7 mRNA expression in circulating tumor cells AM Sieuwerts, B Mostert, M van der Vlugt-Daane, J Kraan, CM Beaufort, ... The Journal of Molecular Diagnostics 20 (3), 316-325, 2018 | 17 | 2018 |
| Tissue-and blood-derived genomic biomarkers for metastatic hormone-sensitive prostate cancer: A systematic review K Van der Eecken, J Vanwelkenhuyzen, MP Deek, PT Tran, E Warner, ... European Urology Oncology 4 (6), 914-923, 2021 | 16 | 2021 |
| Toward methodology for detection of cancer-promoting S100A4 protein conformations in subnanomolar concentrations using Raman and SERS S Abdali, B De Laere, M Poulsen, M Grigorian, E Lukanidin, J Klingelhofer The Journal of Physical Chemistry C 114 (16), 7274-7279, 2010 | 16 | 2010 |
| Androgen receptor burden and poor response to abiraterone or enzalutamide in TP53 wild-type metastatic castration-resistant prostate cancer B De Laere, P Rajan, H Grönberg, L Dirix, J Lindberg JAMA oncology 5 (7), 1060-1062, 2019 | 15 | 2019 |
| Has the PROPHECY of AR-V7 been fulfilled? B De Laere, P Ost, H Gronberg, J Lindberg Journal of Clinical Oncology 37 (24), 2181-2182, 2019 | 9 | 2019 |
| Automated enumeration and phenotypic characterization of CTCs and tdEVs in patients with metastatic castration resistant prostate cancer S Oeyen, V Liégeois, B De Laere, A Buys, M Strijbos, P Dirix, P Meijnders, ... Prostate Cancer and Prostatic Diseases 24 (2), 499-506, 2021 | 5 | 2021 |
| Evaluation of a marker independent isolation method for circulating tumor cells in esophageal adenocarcinoma A Philippron, L Depypere, S Oeyen, B De Laere, C Vandeputte, P Nafteux, ... PLoS One 16 (5), e0251052, 2021 | 5 | 2021 |
| HER-2 status of circulating tumor cells in a metastatic breast cancer cohort: A comparative study on characterization techniques A Brouwer, B De Laere, PJ van Dam, D Peeters, J Van Haver, E Sluydts, ... Plos one 14 (9), e0220906, 2019 | 5 | 2019 |
| Clinical trial protocol for ProBio: an outcome-adaptive and randomised multiarm biomarker-driven study in patients with metastatic prostate cancer B De Laere, A Crippa, A Discacciati, B Larsson, J Oldenburg, A Mortezavi, ... European Urology Focus 8 (6), 1617-1621, 2022 | 3 | 2022 |
